A higher risk of liver transplant and death was observed in Ocaliva-treated patients vs those who received placebo.

A Prescription Drug User Fee Act target date of July 24, 2025 has been set for the sNDA application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) ...

(HealthDay News) — Adults receiving chiropractic spinal manipulative therapy (SMT) for tension-type headache have a significantly lower likelihood of butalbital prescription, according to a study ...

The burden of respiratory syncytial virus (RSV) in young children continues to be high in the United States, according to a study published online Dec. 9 in JAMA Pediatrics. Heidi L. Moline, MD, MPH, ...

Health span-lifespan gaps, resulting from health-adjusted life expectancy lagging behind longevity gains, are growing worldwide, with women exhibiting a large ...

Interim data from a phase 3 study evaluating tecovirimat for the treatment of human mpox virus showed the antiviral did not improve time to lesion resolution compared with placebo.

Screening recommended every three years with cervical cytology for women aged 21 to 29 years, every five years with hrHPV screening at age 30 to 65 years ...

(HealthDay News) — Vitamin D 3 supplementation does not significantly reduce the risk for developing diabetes among older adults who are not at high risk for diabetes, according to a study published ...

The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.

Chlorpheniramine maleate 4mg, dextromethorphan HBr 30mg; tabs. Drowsiness, anticholinergic effects, excitability in children.

The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for paltusotine for the treatment and long-term maintenance of acromegaly in adults.

At all time points, consistently high levels of patient satisfaction were observed (>84% reporting much or very much improved).